Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 280 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Study Shows Music Eases Pain and Other Symptoms for Patients Undergoing... June 6, 2019 Regular Exercise May Boost Immune Response and Improve Immunotherapy in Breast... April 13, 2021 Mutation Screening Could Reveal Whether Hormone Treatment Will Work for Breast... April 23, 2021 FDA Granted Accelerated Approval to Belantamab Mafodotin-blmf for Multiple Myeloma August 14, 2020 Load more HOT NEWS ΠΟΝΟΣ EMA Recommends Extension of Indications for Durvalumab in the Management of... Community Surprises Teen Battling Bone Cancer With Brand New Car For... When He Said His Mother-In-Law Was Going To Live In The...
